Legend Biotech to Present CARVYKTI Data at ASCO and EHA
Ticker: LEGN · Form: 6-K · Filed: May 23, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-data, oncology, conference-presentation, drug-development
TL;DR
Legend Biotech dropping new CARVYKTI data at ASCO & EHA for multiple myeloma patients.
AI Summary
Legend Biotech Corporation announced on May 23, 2024, that new and updated clinical data for its CAR-T cell therapy, CARVYKTI® (ciltacabtagene autoleucel), will be presented at the 2024 ASCO Annual Meeting and the 2024 EHA Congress. These presentations will focus on patients with multiple myeloma, highlighting the ongoing development and leadership in CAR-T cell therapy.
Why It Matters
The presentations at major oncology conferences like ASCO and EHA are crucial for showcasing the efficacy and potential of CARVYKTI, potentially influencing treatment guidelines and market adoption for multiple myeloma.
Risk Assessment
Risk Level: low — This filing is an announcement of data presentations at medical conferences, which is standard practice and does not involve immediate financial risk.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) (drug) — CAR-T cell therapy
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (event) — Conference for data presentation
- 2024 European Hematology Association’s (EHA) 2024 Hyb (event) — Conference for data presentation
- Multiple Myeloma (disease) — Patient population for CARVYKTI
FAQ
What specific new or updated data regarding CARVYKTI will be presented at ASCO and EHA?
The press release states that 'new and updated data from the CARTITUDE Clinical Development Program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma' will be presented, but does not specify the exact nature of the data in this filing.
When are the ASCO and EHA meetings scheduled to take place?
The filing does not provide the specific dates for the 2024 ASCO Annual Meeting or the 2024 EHA Congress, only that data will be presented at them.
What is the primary indication for CARVYKTI® mentioned in this filing?
The primary indication mentioned is for patients with multiple myeloma.
What is the filing type and date?
This is a Form 6-K filed on May 23, 2024.
What is Legend Biotech Corporation's principal executive office address?
The principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 15.7 · Accepted 2024-05-23 17:00:07
Filing Documents
- f6k_052324.htm (6-K) — 9KB
- exh_991.htm (EX-99.1) — 58KB
- logo.jpg (GRAPHIC) — 6KB
- 0001171843-24-003086.txt ( ) — 76KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: May 23, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer